Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
PMID: 39276289

Abstract

PURPOSE: We developed a predictive model to assess the risk of major bleeding (MB) within 6 months of primary venous thromboembolism (VTE) in cancer patients receiving anticoagulant treatment. We also sought to describe the prevalence and incidence of VTE in cancer patients, and to describe clinical characteristics at baseline and bleeding events during follow-up in patients receiving anticoagulants.

Authors

  • Andrés J Muñoz Martín
    Medical Oncology Service, Hospital General Universitario Gregorio Marañón Universidad Complutense, Madrid, Spain. andmun13@ucm.es.
  • Ramón Lecumberri
    Hematology Service, Clínica Universidad de Navarra, Pamplona, Spain.
  • Juan Carlos Souto
    Hematology Department, Santa Creu i Sant Pau Hospital, Barcelona, Spain.
  • Berta Obispo
    Oncology Department, Infanta Leonor Hospital, Madrid, Spain.
  • Antonio Sanchez
    Oncology Department, Puerta de Hierro Hospital, Madrid, Spain.
  • Jorge Aparicio
    Oncology Department, Polytechnic and University Hospital of La Fé, Valencia, Spain.
  • Cristina Aguayo
    Oncology Department, Infanta Sofía Hospital, Madrid, Spain.
  • David Gutiérrez
    Centro de Investigación y de Estudios Avanzados (Cinvestav), Unidad Monterrey, Apodaca, Nuevo Leon 66600, Mexico.
  • Andrés García Palomo
    Oncology Department, University Hospital of León, León, Spain.
  • Diego Benavent
    SAVANA Research S.L., Calle de Larra 12, Madrid 28013, Spain.
  • Miren Taberna
    SAVANA Research S.L., Madrid, Spain.
  • María Carmen Viñuela-Benéitez
    Medicine Department, Facultad de Medicina, Universidad Complutense, Madrid, Spain.
  • Daniel Arumi
    Pfizer S.L.U. Medical Department, Madrid, Spain.
  • Miguel Ángel Hernández-Presa
    Pfizer S.L.U. Medical Department, Madrid, Spain.

Keywords

External Resources

Popular Topics
Recent Journals